Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.86
NAS:SPHS's Cash to Debt is ranked lower than
55% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. NAS:SPHS: 1.86 )
Ranked among companies with meaningful Cash to Debt only.
NAS:SPHS' s Cash to Debt Range Over the Past 10 Years
Min: 0.39  Med: 231.07 Max: No Debt
Current: 1.86
F-Score: 1
Z-Score: -21.00
M-Score: -5.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -475.84
NAS:SPHS's ROE (%) is ranked lower than
99% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.76 vs. NAS:SPHS: -475.84 )
Ranked among companies with meaningful ROE (%) only.
NAS:SPHS' s ROE (%) Range Over the Past 10 Years
Min: -2308.71  Med: -98.48 Max: -63.39
Current: -475.84
-2308.71
-63.39
ROA (%) -124.24
NAS:SPHS's ROA (%) is ranked lower than
97% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. NAS:SPHS: -124.24 )
Ranked among companies with meaningful ROA (%) only.
NAS:SPHS' s ROA (%) Range Over the Past 10 Years
Min: -157.85  Med: -74.28 Max: -35.16
Current: -124.24
-157.85
-35.16
ROC (Joel Greenblatt) (%) -71469.88
NAS:SPHS's ROC (Joel Greenblatt) (%) is ranked lower than
99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.07 vs. NAS:SPHS: -71469.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:SPHS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -71469.88  Med: -10535.78 Max: -2506.29
Current: -71469.88
-71469.88
-2506.29
EBITDA Growth (3Y)(%) -49.50
NAS:SPHS's EBITDA Growth (3Y)(%) is ranked lower than
97% of the 564 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.30 vs. NAS:SPHS: -49.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:SPHS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.5  Med: -6.15 Max: 72.7
Current: -49.5
-49.5
72.7
EPS Growth (3Y)(%) -50.00
NAS:SPHS's EPS Growth (3Y)(%) is ranked lower than
96% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. NAS:SPHS: -50.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:SPHS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50  Med: -4.35 Max: 70.4
Current: -50
-50
70.4
» NAS:SPHS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2014

SPHS Guru Trades in Q3 2014

First Eagle Investment 250,000 sh (unchged)
» More
Q4 2014

SPHS Guru Trades in Q4 2014

First Eagle Investment Sold Out
» More
Q2 2015

SPHS Guru Trades in Q2 2015

Jim Simons 35,618 sh (New)
» More
Q3 2015

SPHS Guru Trades in Q3 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SPHS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:JNP, OTCPK:WUYIF, OTCPK:NRIFF, NAS:ADMP, NAS:LPCN, NAS:EPIX, NAS:MEIP, NAS:STDY, OTCPK:ZOMHF, NAS:PTX, NAS:GALT, NAS:CPIX, NAS:OREX, NAS:IMMY, OTCPK:BKIT, NAS:SCYX, NAS:ARDM, NAS:FCSC, NAS:CPHR, OTCPK:MQTRF » details
Traded in other countries:SHS.Canada, BFF1.Germany,
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. The Company is engaged in research and development of products for the treatment of urological diseases. It is currently developing PRX302 for treatment of benign prostatic hyperplasia.

Sophiris Bio Inc was formed in May 2003 under the predecessor to the Business Corporations Act by the amalgamation of Stratos Biotechnologies Inc., Nucleus BioScience Inc. and Brightwave Ventures Inc. It began operations on January 11, 2002. The Company's operations were initially located in Vancouver, British Columbia. Effective April 2, 2012, the Company changed its name from Protox Therapeutics Inc. to Sophiris Bio Inc. The Company is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of urological diseases. It is currently developing PRX302 for treatment of the symptoms of benign prostatic hyperplasia. BPH is a non-cancerous enlargement of the prostate gland that commonly affects men who are age 50 and older. The Company expects that PRX302 will compete with the current treatment options for the symptoms of BPH, which include oral drug therapy and surgery. Its business and operations are subject to a variety of U.S. federal, state and local, and foreign supranational, national, provincial and municipal laws, regulations and trade practices. As of December 31, 2012, it had nine full-time employees and one part-time employee.

Ratios

vs
industry
vs
history
P/B 94.70
SPHS's P/B is ranked lower than
99% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. SPHS: 94.70 )
Ranked among companies with meaningful P/B only.
SPHS' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 0.94 Max: 94.7
Current: 94.7
0.18
94.7
Current Ratio 3.02
SPHS's Current Ratio is ranked higher than
60% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. SPHS: 3.02 )
Ranked among companies with meaningful Current Ratio only.
SPHS' s Current Ratio Range Over the Past 10 Years
Min: 0.6  Med: 5.3 Max: 118.33
Current: 3.02
0.6
118.33
Quick Ratio 3.02
SPHS's Quick Ratio is ranked higher than
68% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. SPHS: 3.02 )
Ranked among companies with meaningful Quick Ratio only.
SPHS' s Quick Ratio Range Over the Past 10 Years
Min: 0.6  Med: 5.3 Max: 118.33
Current: 3.02
0.6
118.33

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -76.20
SPHS's 3-Year Average Share Buyback Ratio is ranked lower than
96% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. SPHS: -76.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SPHS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -235.3  Med: -63.5 Max: -23.5
Current: -76.2
-235.3
-23.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 107.33
SPHS's Price/Net Cash is ranked lower than
92% of the 201 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.90 vs. SPHS: 107.33 )
Ranked among companies with meaningful Price/Net Cash only.
SPHS' s Price/Net Cash Range Over the Past 10 Years
Min: 0.77  Med: 2.79 Max: 107.33
Current: 107.33
0.77
107.33
Price/Net Current Asset Value 107.33
SPHS's Price/Net Current Asset Value is ranked lower than
97% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.54 vs. SPHS: 107.33 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SPHS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.62  Med: 1.86 Max: 107.33
Current: 107.33
0.62
107.33
Price/Tangible Book 107.33
SPHS's Price/Tangible Book is ranked lower than
98% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. SPHS: 107.33 )
Ranked among companies with meaningful Price/Tangible Book only.
SPHS' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.62  Med: 1.86 Max: 107.33
Current: 107.33
0.62
107.33
Earnings Yield (Greenblatt) (%) -17.19
SPHS's Earnings Yield (Greenblatt) (%) is ranked lower than
89% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. SPHS: -17.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SPHS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -18.8  Med: 39.1 Max: 1287.4
Current: -17.19
-18.8
1287.4

More Statistics

EPS (TTM) $ -0.71
Beta1.78
Short Percentage of Float11.22%
52-Week Range $0.67 - 8.55
Shares Outstanding (Mil)22.62

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) 0.17
EPS w/o NRI ($) 0.17
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:SPHS

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: STRA, IMI, HXM, SPHS Jan 06 2014 
From The Land of What If - Smart Proteins and Debt Collectors Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 

More From Other Websites
Sophiris Bio, Inc. :SPHS-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016 Sep 20 2016
Sophiris Bio (SPHS) Stock Coverage Initiated at Roth Capital Sep 15 2016
Coverage initiated on Sophiris Bio by ROTH Capital Sep 15 2016
SPHS: Initiating on Sophiris Bio, Inc.; Developing Novel Treatments for Urologic Conditions Sep 12 2016
5 Speculative Biotech Analyst Stocks Under $10 With Massive Upside Sep 04 2016
Top Analyst Upgrades and Downgrades: Apple, BHP Billiton, Broadcom, McDonald’s, Sophiris, Tech... Aug 30 2016
Sophiris Bio Closes Underwritten Public Offering Aug 26 2016
Sophiris Bio Closes Underwritten Public Offering Aug 26 2016
Sophiris Bio Inc. (NASDAQ:SPHS): Sabby Capital Reports Large New Stake Aug 25 2016
Look Out Below! What’s the Deal With These 5 Falling Stocks? Aug 23 2016
Sophiris Bio's stock plunges to pace Nasdaq losers after discounted share offering Aug 23 2016
Sophiris Bio (SPHS) Stock Tumbles on Public Offering Aug 23 2016
Sophiris Bio Prices Public Offering of Common Shares and Warrants Aug 23 2016
Sophiris Bio Prices Public Offering of Common Shares and Warrants Aug 23 2016
Sophiris Bio shares tank on secondary stock offering Aug 22 2016
Sophiris Bio Announces Proposed Public Offering of Common Shares and Warrants Aug 22 2016
Sophiris Bio Announces Proposed Public Offering of Common Shares and Warrants Aug 22 2016
Sophiris Bio Reports Second Quarter 2016 Financial Results and Key Business Highlights Aug 09 2016
Sophiris Bio Reports Second Quarter 2016 Financial Results and Key Business Highlights Aug 09 2016
eBay, AMD Head the List of Nasdaq Stocks Hitting 52-Week Highs Friday Jul 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)